A Phase 2 interventional study of Cilofexor and Placebo to match cilofexor in Primary Sclerosing Cholangitis, sponsored by Gilead Sciences. Completed at 23 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-07.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 23rd largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2016, is one of 26 in phase 2, and was the 32nd registered.
150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.
Browse Cholangitis, Sclerosing studies →19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:
Ipsen · Sites in United States, Argentina, Australia and 22 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–68 · Healthy volunteers
LISCure Biosciences · Sites in United States
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Elizabeth C. Verna · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 31 · Phase 3 6
First in 1997; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is above the median of 33 across 95 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 27 across the 57 interventional studies, 129 across the 18 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 75 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
4 of the studies in Cholangitis, Sclerosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT05295680Aparna GoelOral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | 2027-05 |
| NCT05835505Brigham and Women's HospitalDetoxification of the Liver In PSC (Dolphin) | 2027-05-01 |
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary sclerosing cholangitis (PSC).
Key Inclusion Criteria:
Key Exclusion Criteria:
Cirrhosis of the liver as defined by any of the following:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
Drug: Cilofexor · Drug: Placebo to match cilofexor
Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
Drug: Cilofexor · Drug: Placebo to match cilofexor
Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
Drug: Placebo to match cilofexor
Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
Drug: Cilofexor
Tablet(s) administered orally once daily with food
Also known as: GS-9674
Tablet(s) administered orally once daily with food
Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase
Treatment-emergent adverse events occurring during the Blinded Phase were defined as 1 or both of the following: 1) Any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug in the Blinded Phase (and before the first dosing date in the Open Label Extension (OLE) Phase), or 2) Any AEs leading to premature discontinuation of study drug in the Blinded Phase.
Time frame: First dose date up to last dose date plus 30 days (Up to 17 weeks)
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events During the Blinded Phase
A serious adverse event was defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction.
Time frame: First dose date up to last dose date plus 30 days (Up to 17 weeks)
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities During the Blinded Phase
Treatment-emergent laboratory abnormalities occurring during the Blinded Phase were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug in the Blinded Phase plus 30 days (and prior to or on the first dose date of the OLE phase). The Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 was used for assigning toxicity grades (0 to 4, with higher grades indicating more severity).
Time frame: First dose date up to last dose date plus 30 days (Up to 17 weeks)
Participants were enrolled at study sites in North America and Europe. The first participant was screened on 29 November 2016. The last study visit occurred on 18 May 2020.
| Milestone | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Started | 22 | 20 | 10 |
| Completed | 19 | 19 | 10 |
| Not completed | 3 | 1 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 |
| Milestone | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Started | 19 | 18 | 10 |
| Completed | 14 | 11 | 8 |
| Not completed | 5 | 7 | 2 |
| Withdrew: Adverse event | 2 | 5 | 2 |
| Withdrew: Withdrew consent | 2 | 1 | 0 |
| Withdrew: Investigator's discretion | 1 | 1 | 0 |
Treatment-emergent adverse events occurring during the Blinded Phase were defined as 1 or both of the following: 1) Any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug in the Blinded Phase (and before the first dosing date in the Open Label Extension (OLE) Phase), or 2) Any AEs leading to premature discontinuation of study drug in the Blinded Phase.
| percentage of participants | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase | 81.8 | 70.0 | 100.0 |
A serious adverse event was defined as an event that, at any dose, resulted in any of the following: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction.
| percentage of participants | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events During the Blinded Phase | 13.6 | 0 | 0 |
Treatment-emergent laboratory abnormalities occurring during the Blinded Phase were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug in the Blinded Phase plus 30 days (and prior to or on the first dose date of the OLE phase). The Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 was used for assigning toxicity grades (0 to 4, with higher grades indicating more severity).
| percentage of participants | Cilofexor 100 mg | Cilofexor 30 mg | Placebo |
|---|---|---|---|
| Any Grade 1 or Higher | 90.9 | 85.0 | 100.0 |
| Grade 1 | 22.7 | 25.0 | 10.0 |
| Grade 2 | 36.4 | 35.0 | 60.0 |
| Grade 3 | 27.3 | 20.0 | 30.0 |
| Grade 4 | 4.5 | 5.0 | 0 |
Collected over Blinded Phase: First dose date up to last dose date plus 30 days (Up to 17 weeks); OLE Phase: First dose date up to last dose date plus 30 days (Up to 102 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cilofexor 100 mg (Blinded Phase) | 0/22 (0%) | 3/22 (13.6%) | 18/22 (81.8%) |
| Cilofexor 30 mg (Blinded Phase) | 0/20 (0%) | 0/20 (0%) | 14/20 (70%) |
| Placebo (Blinded Phase) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Cilofexor 100 mg (Open Label Extension Phase) | 0/47 (0%) | 10/47 (21.3%) | 41/47 (87.2%) |
| Event | Cilofexor 100 mg (Blinded Phase) | Cilofexor 30 mg (Blinded Phase) | Placebo (Blinded Phase) | Cilofexor 100 mg (Open Label Extension Phase) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/22 | 0/20 | 0/10 | 0/47 |
| Rib fractureInjury, poisoning and procedural complications | 1/22 | 0/20 | 0/10 | 0/47 |
| DehydrationMetabolism and nutrition disorders | 1/22 | 0/20 | 0/10 | 0/47 |
| Acute kidney injuryRenal and urinary disorders | 1/22 | 0/20 | 0/10 | 0/47 |
| Bile duct obstructionHepatobiliary disorders | 0/22 | 0/20 | 0/10 | 2/47 |
| Abdominal painGastrointestinal disorders | 0/22 | 0/20 | 0/10 | 1/47 |
| Abdominal pain lowerGastrointestinal disorders | 0/22 | 0/20 | 0/10 | 1/47 |
| Abdominal pain upperGastrointestinal disorders | 0/22 | 0/20 | 0/10 | 1/47 |
| Chest painGeneral disorders | 0/22 | 0/20 | 0/10 | 1/47 |
| Cholangitis sclerosingHepatobiliary disorders | 0/22 | 0/20 | 0/10 | 1/47 |
| Event | Cilofexor 100 mg (Blinded Phase) | Cilofexor 30 mg (Blinded Phase) | Placebo (Blinded Phase) | Cilofexor 100 mg (Open Label Extension Phase) |
|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 8/22 | 5/20 | 6/10 | 20/47 |
| NauseaGastrointestinal disorders | 0/22 | 1/20 | 3/10 | 5/47 |
| NasopharyngitisInfections and infestations | 5/22 | 5/20 | 2/10 | 14/47 |
| FatigueGeneral disorders | 3/22 | 3/20 | 2/10 | 6/47 |
| Alanine aminotransferase increasedInvestigations | 0/22 | 0/20 | 2/10 | 1/47 |
| Aspartate aminotransferase increasedInvestigations | 0/22 | 0/20 | 2/10 | 2/47 |
| HeadacheNervous system disorders | 1/22 | 4/20 | 2/10 | 7/47 |
| Abdominal pain upperGastrointestinal disorders | 4/22 | 2/20 | 1/10 | 5/47 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/22 | 1/20 | 1/10 | 5/47 |
| Abdominal discomfortGastrointestinal disorders | 2/22 | 0/20 | 1/10 | 4/47 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 42 ± 8.6 | 46 ± 12.1 | 42 ± 10.9 | 43 ± 10.4 |
| Sex: Female, Male(Participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 11 | 6 | 5 | 22 |
| Male | 11 | 14 | 5 | 30 |
| Race/Ethnicity, Customized(Participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Race — Asian | 0 | 2 | 1 | 3 |
| Race — Black or African American | 4 | 3 | 1 | 8 |
| Race — White | 17 | 15 | 7 | 39 |
| Race — Not Permitted | 0 | 0 | 1 | 1 |
| Race — Other | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 3 | 0 | 3 |
| Ethnicity — Not Hispanic or Latino | 21 | 17 | 9 | 47 |
| Ethnicity — Not Permitted | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Cilofexor 100 mg | Cilofexor 30 mg | Placebo | Total |
|---|---|---|---|---|
| Canada | 4 | 2 | 2 | 8 |
| Austria | 1 | 0 | 0 | 1 |
| United States | 12 | 17 | 7 | 36 |
| United Kingdom | 5 | 1 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Feb 2018, 14 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor